Top Bacteriophage Companies

Bacteriophage Market was valued at USD 41.61 Million in 2023 and is poised to grow from USD 43.48 Million in 2024 to USD 61.83 Million by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The global bacteriophage market's competitive landscape is evolving rapidly with a growing number of biotech companies focusing on phage-based therapies and solutions. Established players like Adaptive Phage Therapeutics, Pherecydes Pharma, and Eligo Bioscience lead in research and development. Collaborations between pharmaceutical giants and smaller startups are driving innovation and product pipelines. Regulatory approvals and clinical trials are shaping the market's dynamics, creating opportunities for new entrants. Intellectual property rights and technology acquisitions also influence the landscape. As the antimicrobial resistance crisis intensifies, the Bacteriophage market is expected to witness intensified competition, consolidation, and increased investment in research and commercialization efforts. 'Microgen (U.S.)', 'Micreos (Netherlands)', 'ATCC (U.S.)', 'Intralytix, Inc. (U.S.)', 'Adaptive Phage Therapeutics (U.S.)', 'Armata pharmaceuticals Inc. (U.S.)', 'LOCUS BIOSCIENCES, INC. (U.S.)', 'Delmont Laboratories, Inc. (U.S.)', 'Nextbiotics (U.S.)', 'Pherecydes Pharma (France)', 'iNtODEWORLD. Inc. (U.S.)', 'Enbiotix (U.S.)', 'Fixed-Phage Limited (U.K.)', 'Cytophage Technologies Inc. (Canada)', 'Eliava Bio Preparations LTD (Georgia)', 'Phagelux, Inc. (China)', 'InnoPhage, Ltd (Hong Kong)', 'TechnoPhage (Portugal)', 'Eligo Bioscience SA (France)', 'BiomX Ltd. (Israel)'

The increasing prevalence of antibiotic-resistant bacterial infections has driven the demand for alternative treatment options. Bacteriophages, which are viruses that target and kill specific bacteria, offer a promising avenue for combating antibiotic-resistant bacteria and superbugs. As conventional antibiotics become less effective, the bacteriophage market is propelled by the need for innovative and personalized therapeutic approaches.

Rising Interest in Phage Therapy: There is a growing interest in the use of bacteriophages (viruses that infect and kill bacteria) for therapeutic purposes, known as phage therapy. As antibiotic resistance becomes a critical global health concern, researchers and healthcare professionals are exploring alternative treatments. Bacteriophages have shown potential in targeting specific bacterial infections, especially those resistant to antibiotics. The increasing understanding of phage biology, advances in phage isolation and production, and successful case studies are driving the exploration of phage therapy as a viable medical intervention.

The global bacteriophage market is analyzed based on its regional presence, which includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. In the Bacteriophage Market, North America stands out as a dominant region in terms of market share. The region's advanced healthcare infrastructure, robust research and development activities, and regulatory support for phage therapy contribute to its prominent position. Bacteriophages are gaining traction as potential alternatives to antibiotics, and North America's established pharmaceutical and biotechnology industry accelerates their integration into medical practices.